Hostname: page-component-5cf477f64f-mgq6s Total loading time: 0 Render date: 2025-04-01T08:03:37.662Z Has data issue: false hasContentIssue false
  • English
  • Français

Germ-Line Manipulations, Private Industry, and Secrecy

Published online by Cambridge University Press:  17 May 2016

David B. Resnik
David B. Resnik*
Affiliation:
University of Wyoming, USA
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Roundtable Commentaries
Information
Politics and the Life Sciences , Volume 17 , Issue 1 , March 1998 , pp. 29 - 30
Copyright
Copyright © Association for Politics and the Life Sciences 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Connolly, H. et al.(1997). “Valvular Heart Disease Associated with Fenfluramine-Phentermine.” The New England Journal of Medicine 337:581–88.Google Scholar
Gardner, W. (1995). “Can Human Genetic Enhancement be Prohibited?” Journal of Medicine and Philosophy 20:65–84.Google Scholar
McCain, K. (1991). “Communication, Competition, and Secrecy: The Production and Dissemination of Research-Related Information in Genetics.” Science, Technology, and Human Values 16:492.Google Scholar
Munthe, C. and Welin, S. (1996). “The Morality of Scientific Openness.” Science and Engineering Ethics 2:411–28.Google Scholar
Rubenstein, D. et al.(1995). “Germ-Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation,” Cambridge Quarterly of Healthcare Ethics 4(3):316–39.Google Scholar